Alp Bio AG is a Swiss biotech startup that combines human immune organoid technology with generative AI. The company provides immunogenicity intelligence to detect and mitigate anti-drug antibody (ADA) risks years before clinical trials, helping developers avoid costly late-stage failures.
Products, services, technology
Covering detection to prevention of immunogenicity in preclinical biologics.
- AI-based in silico ADA scoring (license)
- Tonsil organoid ADA risk reporting per asset
- Full antibody optimization programs with milestone-linked success fees.
Cooperation possibilities
Predict: protein language and geometric deep learning models screen sequence panels for high-risk epitopes.
Validate: our human tonsil organoid assay maps B and T cell responses in vitro.
Re-engineer: generative AI redesigns flagged epitopes to cut ADA risk while preserving function.
- http://www.alp.bio
- Send an email
- Punit Mehra
Some insights
We help make biologic drugs safer and more reliable by reducing unexpected immune reactions. This can prevent late-stage failures, save resources, and ultimately improve access to effective treatments for patients.
We are building a human-relevant platform that addresses a real and costly problem in drug development. We combine solid science with practical application and stay honest about both the potential and the limits of our approach.
Our strengths are immunology, AI-based protein modeling, and business development in biotech. We aim to add expertise in regulatory strategy, clinical development, and scaled lab operations.
We try to make medicines less likely to cause unwanted immune reactions by testing and redesigning them before they reach patients.
Through early partnerships, access to translational funding, and connections to pharma and CRO partners for validation studies and pilot projects.
Preclinical antibody teams in biotech and pharma, CROs, immunogenicity experts, translational researchers, and investors with experience in platform biotech.
